Eton Pharmaceuticals, Inc.

ETON · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders4.9%

Institutions70.3%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$79.95M	$39.01M	$31.64M	$21.83M	$39000	$959000	–
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$37.21M	$15.60M	$10.58M	–	$286000	$453000	–
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	$42.74M	$23.41M	$21.06M	$19.21M	-$247000	$506000	–
Gross profit as a percentage of revenue.	53.5%	60.0%	66.6%	88.0%	-633.3%	52.8%	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$844000	-$2.60M	-$1.19M	-$1.50M	-$27.11M	-$18.60M	-$10.32M
Operating income as a percentage of revenue.	-1.1%	-6.7%	-3.8%	-6.8%	-69515.4%	-1939.6%	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$4.60M	-$3.82M	-$936000	-$1.96M	-$27.97M	-$18.32M	-$37.23M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-0.17	$-0.15	$-0.04	$-0.08	$-1.33	$-1.00	$-5.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$25.94M	$14.94M	$21.39M	$14.41M	$21.30M	$12.07M	$26.73M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$92.11M	$76.12M	$31.74M	$27.46M	$26.32M	$17.07M	$28.33M
All of the company's interest-bearing borrowings, short and long term combined.	$30.56M	$0	$5.38M	$1.42M	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$65.96M	$51.70M	$16.26M	$9.84M	$10.66M	$6.52M	$2.02M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$26.15M	$24.43M	$15.48M	$17.63M	$15.66M	$10.55M	$26.30M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$10.52M	$969000	$6.82M	-$4.72M	-$22.35M	-$18.03M	-$8.14M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$333000	$26000	$0	$9000	$50000	$1.10M	$236000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$10.19M	$943000	$6.82M	-$4.73M	-$22.40M	-$19.12M	-$8.38M

	You	Peer avg
P/E	149.9	–
Revenue Growth	+98.6%	+11191.6%
ROE	36.0%	-26.2%

Eton Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison